Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Athena Diagnostics Inc | RCV000201026 | SCV000255894 | likely pathogenic | Tuberous sclerosis 2 | 2015-06-16 | criteria provided, single submitter | clinical testing | |
| Gene |
RCV000414012 | SCV000491161 | likely pathogenic | not provided | 2016-03-24 | criteria provided, single submitter | clinical testing | A G1204E variant that is likely pathogenic has been identified in the TSC2 gene. The G1204E variant has been reported previously in association with tuberous sclerosis complex; however, information about parental testing was not provided (Au et al., 2007; vanEeghen et al., 2013; TSC2 LOVD). Functional studies indicate that G1204E is pathogenic (Hoogeveen-Westerveld et al., 2011). It was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The G1204E variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position where amino acids with similar properties to Glycine are tolerated across species. Additionally, in silico analysis predicts this variant is probably damaging to the protein structure/function. Furthermore, missense variants in nearby residues (V1199G, R1200W, P1202H/R, T1203K) have been reported in the Human Gene Mutation Database in association with tuberous sclerosis (Stenson et al., 2014), supporting the functional importance of this region of the protein. Therefore, this variant is likely pathogenic; however, the possibility that it is benign cannot be excluded. |
| Tuberous sclerosis database |
RCV000043416 | SCV000067222 | not provided | Tuberous sclerosis syndrome | no assertion provided | curation |